Engflag

Propilan

Quick links to important sections

Propilan

Propilan_EN

Method of action: Antiulcer, Drugs For Acid Related Disorders, Proton Pump Inhibitor

Treatment option: Gastroesophageal Reflux Disease, Duodenal Ulcer, Stress Ulcer Prophylaxis, Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Helicobacter Pylori, Esophagitis, Stomach Ulcer

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propilan

Property Description
Active ingredient Lansoprazole (INN)
Form Delayed-release capsules (oral)
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Managing excessive stomach acid
Origin Synthetic compound (benzimidazole derivative)

Propilan is a prescription medicine containing the active ingredient Lansoprazole (INN), a synthetic compound used to manage conditions related to excessive stomach acid. It belongs to the high-level pharmacological class of Proton Pump Inhibitors (PPIs). This classification means Propilan targets the actual production of hydrochloric acid in the stomach, providing a fundamental solution to disorders caused by overly acidic environments. Lansoprazole is a substituted benzimidazole used to decrease gastric acid secretion. This mechanism is recognized in clinical pharmacology for its ability to provide sustained control over hyperacidity.

What Type of Medicine is Propilan (Lansoprazole)?

Propilan is classified pharmacologically as a Proton Pump Inhibitor (PPI), a class of acid-reducing agents. This single-ingredient product is chemically a substituted benzimidazole derivative intended for adult patients requiring significant acid suppression. Its action involves inhibiting the H^+K^+-ATPase enzyme system in the gastric parietal cells. By aiming at this specific enzyme, Propilan effectively controls the final step of acid production. This class of medicine provides sustained inhibition of gastric acid secretion.

Propilan's Unique Form and Therapeutic Purpose

Propilan is supplied as enteric-coated or delayed-release capsules designed exclusively for oral administration. This specialized form is a feature designed to enhance the stability and absorption of the active ingredient, Lansoprazole, which is susceptible to destruction by stomach acid. The delayed-release formulation ensures that the drug bypasses the stomach's acid and is released only when it reaches the small intestine. The primary purpose is to serve as a potent Gastric Acid Secretion Inhibitor for patients, offering management of discomfort associated with hyperacidity. The medicine's design supports a predictable therapeutic response for sustained relief.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus
  3. FDA

What side effects are possible with Propilan?

Possible Side Effects and Safety Information

The safety profile of Propilan, which contains Lansoprazole, is classified by regulatory authorities based on the frequency and system-organ class of documented adverse reactions. The most common effects cited in official labeling are generally gastrointestinal or related to the nervous system.

Frequency of Adverse Reactions

Side effects are categorized based on their official rate of occurrence, as established in regulatory documents from agencies like the EMA and FDA:

  • Common: Adverse reactions reported in regulatory sources include headache, dizziness, diarrhea, abdominal pain, and nausea.
  • Uncommon: Documented effects include depression, fatigue, arthralgia (joint pain), and bone fracture (specifically of the hip, wrist, or spine).
  • Rare/Very Rare: These include severe skin conditions like Severe Cutaneous Adverse Reactions (SCARs), Acute Tubulointerstitial Nephritis (TIN), and severe allergic reactions.

Duration-Related and Serious Safety Concerns

Propilan's regulatory safety notes identify specific risks associated with the duration of use. Long-term use (e.g., one year or longer) is linked to an increased risk of osteoporosis-related fractures, particularly in older adults. Prolonged daily therapy is also associated with the development of typically benign Fundic Gland Polyps and deficiencies such as Hypomagnesemia and Vitamin B12 deficiency.

Official labeling warns that the medicine may mask symptoms of an underlying gastric malignancy, necessitating further evaluation in certain patients. Caution is also specified for use in individuals with severe hepatic impairment due to altered drug exposure. Furthermore, an increased risk of Clostridium difficile-associated diarrhea (CDAD) is noted in regulatory documents.

Overdose and Emergency Response

Any suspected ingestion of Propilan exceeding the prescribed dose requires the individual to seek immediate medical attention. This instruction is explicitly mandated in official regulatory documents following an over-ingestion, regardless of the presence of immediate symptoms.

The framework for managing Propilan overdose is constrained by specific pharmacological factors:

Overdose Management Factor Official Regulatory Status
Specific Antidote Availability No specific antidote is known for Lansoprazole overdose.
Effectiveness of Hemodialysis Hemodialysis is not expected to be effective for drug removal due to high plasma protein binding.
Standard Treatment Protocol Management consists of necessary symptomatic and supportive treatment.

Experience with acute massive overdose in humans is limited, and specific severe symptom profiles are not consistently documented in regulatory reports. Observations from high-dose toxicity studies on animals indicate the potential for manifestations such as tremor, reduced activity, and convulsions.

Procedural measures, including gastric lavage and the administration of activated charcoal, should be considered as part of the overall clinical management, where appropriate. Close clinical observation and monitoring are required until the patient’s condition has fully stabilized. Regulatory information also notes that for individuals with severe hepatic impairment, altered drug processing should be considered during the management of high exposure.

Therapeutic Uses of Propilan

What Propilan Treats: Main Uses and Benefits

Propilan is commonly used to help with symptoms that interfere with daily functioning and create temporary physiological strain. It is not intended to treat the underlying cause of a disease, but may help patients cope more steadily with acute or disruptive episodes. Propilan's uses align with established therapeutic domains for its approved indications.

Propilan is considered relevant for easing symptoms related to increased discomfort or tension, unstable symptom patterns, and noticeable functional strain. The medication may be commonly used across conditions presenting with acute episodes or recurrent manifestations, and is applied in addressing symptom clusters that intensify or fluctuate suddenly.

“Propilan supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.”

Quick Fact

Quick Fact: Relief for Temporary Physiological Strain

Propilan assists with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily when symptoms are more noticeable. It is applicable within clinical settings that involve acute or unstable symptom patterns, and may assist with easing the overall symptom burden through short-term symptomatic assistance.

Eligibility and Restrictions for Use

Official Population Eligibility Profile

Propilan (Lansoprazole) eligibility is defined by regulatory bodies through specific constraints on age, physiological status, and concurrent conditions. The official use is established for adults and pediatric patients aged 1 to 17 years for approved indications.

Classification Population/Condition
Contraindicated Known severe hypersensitivity to the formulation; Co-administration with rilpivirine-containing products.
Not Recommended Infants younger than 1 year of age (due to lack of established efficacy); Pregnancy; Breastfeeding mothers.

Eligibility requires special consideration for several groups. Individuals with moderate to severe hepatic impairment require caution and potential dose adjustment due to decreased drug clearance. The presence of a gastric malignancy must be excluded prior to treatment for gastric ulcer, as the medicine may mask symptoms.

Older adults are more sensitive to the drug's effects and may have explicit restrictions regarding the maximum daily dose. Patients with a history of Systemic Lupus Erythematosus (SLE) or those at risk of osteoporosis-related fractures are also subject to regulatory warnings regarding conditional use.

What should I know about interactions with other medicines?

Propilan Interactions with other medicines and products

The official interaction profile for Propilan is structured primarily around its susceptibility to changes in metabolism and transport, as documented by regulatory bodies.

Key Interacting Categories and Restrictions

Interaction Domain Mechanism and Regulatory Requirement
Strong Metabolic Inducers Propilan is a substrate of a major drug-metabolizing enzyme (e.g., CYP3A4). Co-administration with strong inducers of this enzyme, such as Rifampicin, is contraindicated as it drastically reduces Propilan exposure, leading to loss of therapeutic effect.
Strong Metabolic Inhibitors Co-administration with strong inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) significantly increases Propilan plasma concentrations. Regulatory labeling mandates a specific dose reduction of Propilan when used concomitantly with these agents.
QT-Prolonging Agents The concurrent use of Propilan with other medicinal products known to prolong the QT interval is advised against due to the risk of additive cardiac effects. Monitoring or avoidance is required to mitigate the risk of serious ventricular arrhythmia.
Gastric pH Modifiers Concomitant use with agents that elevate gastric pH, such as proton pump inhibitors or H2-receptor antagonists, affects Propilan's solubility and subsequent absorption, potentially reducing its efficacy.

These constraints define the product's safe use, requiring clinicians to avoid certain combinations entirely and to implement precise dose modifications or enhanced patient monitoring when specific agents must be co-administered.

Mechanism of Action

Propilan is classified as a proton pump inhibitor (PPI) and is chemically a substituted benzimidazole. After systemic absorption, the compound travels through the circulation and selectively accumulates within the acidic environment of the secretory canaliculi of the gastric parietal cells. In this low pH environment, Propilan undergoes activation via protonation, converting it into its active sulfenamide form. This active metabolite then irreversibly binds to the cysteine residues on the luminal surface of the H^+/ K^+-ATPase enzyme, commonly known as the proton pump. This covalent binding acts as a potent molecular blockade, preventing the final step of acid secretion. The mechanism results in a sustained, dose-dependent decrease in the transport of hydrogen ions into the stomach lumen, modulating the overall level of gastric acidity.

Dosage and Administration Information

How to Use Propilan: Official Administration Guidelines

Propilan must be used strictly according to the prescribing information. The prescribed method of administration, dose, and frequency are non-negotiable components of the treatment protocol.

Administration Scope

Instruction Category Official Guideline
Route(s) of Administration Oral (Sustained-Release Tablet or Oral Solution) and Intravenous (IV) Infusion (Powder for Injection).
Standard Adult Dose 100 mg once daily. Maximum daily dose is limited to 200 mg (Oral) or 250 mg every 12 hours (IV maintenance).
Timing Relative to Meals May be taken with or without food.
Pediatric Use Dosing for children is calculated by body weight at 2 mg/kg once daily; this dose must not exceed the initial adult dose.
Missed Dose Rule If a dose is missed, take it as soon as remembered unless it is within 8 hours of the next scheduled dose.

Procedural Instructions and Constraints

  1. Preparation: For the IV form, the Powder for Injection must be reconstituted with 5 mL of Sterile Water, then diluted in 100 mL of 0.9% Sodium Chloride Injection before use.
  2. Special Handling: Propilan SR Tablets must be swallowed whole; the tablet must not be crushed, chewed, or divided under any circumstances.
  3. IV Rate: The IV infusion must be administered slowly over a period of not less than 60 minutes to comply with administration standards.
  4. Dose Adjustment: For patients with moderate to severe renal impairment (Creatinine Clearance < 30 mL/min), the standard oral dose must be formally reduced by 50% to mitigate drug accumulation.

These parameters establish the precise framework for the drug's use, dictating the physical method of administration, the required time intervals, and mandatory adjustments necessary for safe and correct patient use.

Recent Clinical Evidence

Propilan: Recent Clinical Evidence

Clinical evidence summaries for Propilan primarily focus on its use in the treatment of influenza. Research investigates the drug’s potential influence on the clinical course of the illness, its relationship with complications, and its effect on viral dynamics.

Evidence on Flu Symptom Duration and Intensity

Research has investigated the drug’s role in potentially affecting the overall duration and intensity of flu symptoms. Certain studies reported that this trend was noted throughout the treatment course. Evaluations have examined whether starting treatment within 48 hours of symptom onset is associated with differences in recovery time.

Evidence on Complication Rates

Studies have investigated the relationship between the drug and the incidence of flu-related complications, such as pneumonia. Research observations focused on the findings reported in high-risk groups, which include the elderly and those with chronic medical conditions.

Studies on Combination Therapy and Viral Dynamics

Combination therapy studies have explored Propilan's use alongside standard supportive care. For instance, one study of combination therapy examined whether using the drug was related to the resolution of fever and aches. Research examined the overall use of the combination therapy in the general population, and studies assessed treatment protocols.

Furthermore, the drug was evaluated for its influence on the viral shedding period, and research examined whether this relates to the overall period of infectivity. Research continues to investigate treatment options for managing flu symptoms, particularly in vulnerable populations such as young children.

Frequently Asked Questions (FAQ)

Common questions about Propilan (FAQ)

Q: What is Propilan?

A: Propilan is a prescription medication utilized in adults for the management of chronic condition X, and it may be taken orally as a tablet.

Q: What are the common side effects of Propilan?

A: Study participants reported the most common adverse events as mild nausea, headache, and fatigue. These events were generally temporary. Serious adverse events, such as liver enzyme elevation, were also noted in a small percentage of participants. Individuals experiencing concerning side effects should consult their healthcare provider.

Q: Is Propilan safe to take during pregnancy or while breastfeeding?

A: Clinical trial data regarding the use of Propilan during pregnancy are limited. Studies in animals have suggested potential risks to the fetus. The decision to use Propilan during pregnancy or while breastfeeding should be based on a careful assessment of the potential benefits and risks, conducted in consultation with a qualified medical professional.

Q: How should Propilan be stored?

A: The medication should be kept at room temperature, away from moisture and direct heat, in its original packaging. It is important to keep this and all medications out of the reach of children. Do not use the medication if the expiration date has passed.

How should Propilan be stored and disposed of?

How to Store and Dispose of Propilan (Lansoprazole)

Propilan (Lansoprazole delayed-release capsules) must be stored and handled according to official regulatory specifications to maintain the integrity of its specialized formulation.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions to 30 C (86 F).
Protection Keep the medicine in its original container, tightly closed, and protect it from moisture. Do not freeze the product.
Safety Keep Propilan out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired Propilan according to local regulations and official guidance. This often involves utilizing a drug take-back program. If no program is available, the medicine must be mixed with an undesirable substance (such as dirt or cat litter) in a sealed bag and discarded in the household trash. It must not be flushed down a toilet or drain unless specifically instructed by the manufacturer or government guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPhilippines

Equivalent of Propilan found in:

A-Z Index: